Trials / Completed
CompletedNCT02158169
Biosimilar Retacrit® in the Treatment of Chemotherapy-induced Anaemia in Oncology and Haematology
Pharmaco-epidemiological Study on the Effect of Retacrit® on Chemotherapy Induced Anaemia in Standard Oncology and Haematology Practice: Impact of Concomitant Iron Supplementation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,167 (actual)
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to describe, in a real-life context, the impact of an epoetin alpha biosimilar, Retacrit®, on anaemia in patients receiving chemotherapy, according to concomitant iron supplementation.
Detailed description
This is a longitudinal, observational, prospective, multicentre, cohort study, conducted on a representative sample of public and/or private hospital-based oncologists and haematologists practicing in Metropolitan France.
Conditions
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2014-06-06
- Last updated
- 2015-07-28
Locations
69 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02158169. Inclusion in this directory is not an endorsement.